TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial

* Inclusion Criteria: * ≥18 years, all race/ethnic groups in China； * Newly diagnosed and previously untreated (patients are allowed to have received oral prednisone for up to 1 week before enrollment) symptomatic MCD patients (symptomatic disease is defined by the presence of clinical symptoms with the NCI-CTCAE grading ≥1 that are attributable to the disease, and for which treatment is indicated); * Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2; * Clinical laboratory values meeting these criteria at screening: absolute neutrophil count ≥ 1•0 x 109/L, Platelets ≥ 50 x 109/L, Alanine aminotransferase (ALT) within 2•5 x upper limit of normal (ULN); total bilirubin within 2•5 x ULN; estimated glomerular filtration rate (according to MDRD formula) \<15ml/min; * Women of childbearing potential must agree to use birth control measures during the study and for at least 3 months after receiving the last dose of study agent, and must have a negative pregnancy test at screening period. Men must agree to use birth control measures during the study and for at least 3 months after receiving the last dose of study agent; * Informed consent must be signed. * Exclusion Criteria: * age under 18 years; * ECOG (eastern cooperative oncology group) status above 2; * Immunosuppressive or anti-neoplastic drugs within the last 3 months; * serious diseases including malignancy; * Plan to have babies within 1 year after enrollment (for women and men), or preg…